YH

Yoram Harth

Democratizing Dermatology with AI, Co-founder, Chief Medical Officer at MDalgorithms the company behind MDacne and MDhair

San Francisco Bay Area

Invests in

Stages:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Education

Work Experience

  • Cofounder, Chief Medical Officer

    2017

    MDalgorithms' mission is to democratize dermatology with AI and provide people with skin conditions with effective, accessible, and affordable treatment. MDalgorithms' first offering, MDacne, is the world's first direct-to-consumer acne treatment service that utilizes a fully customized approach. By utilizing the MDacne app, users can take a selfie and receive a personalized treatment kit, fine-tuning, and 24/7 support. The company has also introduced MDhair, its second brand. MDhair is the world's first computer imaging-based customized hair loss treatment. Using deep learning and image analysis, as well as over 100 medicated and plant-based ingredients, individuals with hair loss can receive personalized treatment targeted at the root cause and severity of their condition.

  • Fellow and former faculty member

    1991

2007 - 2017

  • Cofounder, Chief Medical Officer

    2007 - 2017

    EndyMed Medical Ltd. is a publicly traded company on the Israeli stock exchange (TASE: ENDY) that specializes in energy-based medical aesthetic treatment systems for both professional and consumer markets. Since its establishment in 2007, the company has gained global recognition for its innovative products and technologies, which are considered the gold standard in the industry. With over 40 distribution channels worldwide, EndyMed has a strong global presence and boasts a portfolio of proprietary IP, including 11 registered patents and 10 patent applications. The company's 3DEEP technology is clinically proven and supported by comprehensive and consistent clinical training worldwide.

1988 - 1995

  • Cofounder, Chief Medical Officer

    1988 - 1995

    CureLight, a medical technology company, has made a significant impact in the field of light therapy for the treatment of skin conditions. The company received FDA approval for the use of light therapy for the treatment of acne, becoming the first ever company to receive such approval. CureLight's team, led by Dr. Yoram Harth, initiated the first clinical studies and commercialized its line of acne treatment systems worldwide. This innovation was recognized as a top innovation of the year by the Wall Street Journal Europe in 2003. In addition to its pioneering work in acne treatment, CureLight is also a leader in the development of targeted phototherapy for psoriasis and vitiligo. Its Multiclear system delivers high-intensity light in four different wavelengths through a liquid fiber, allowing for fast and effective treatment for small lesions of psoriasis and vitiligo. This method is safer and faster than traditional full-body UV light boxes. CureLight's third line of products, iClear XL and Cellulite, enables skin rejuvenation and treatment of cellulite with high-intensity red and infrared light.